EFFICACY OF THROMBOLYTIC THERAPY IN PRESERVING LEFT VENTRICULAR FUNCTION FOLLOWING ACUTE MYOCARDIAL INFARCTION

Similar documents
OUTCOME OF THROMBOLYTIC AND NON- THROMBOLYTIC THERAPY IN ACUTE MYOCARDIAL INFARCTION

The First 12 Hours. ST-Segment Elevation AMI: Introduction. Definitions

Journal of the American College of Cardiology Vol. 37, No. 6, by the American College of Cardiology ISSN /01/$20.

Acute Myocardial Infarction

Acute coronary syndromes

Ischemic heart disease

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

When the learner has completed this module, she/he will be able to:

Diagnosis and Management of Acute Myocardial Infarction

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

Management of Acute Myocardial Infarction

Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-pa and streptokinase

Myocardial Infarction

Time delays in instituting thrombolysis in acute myocardial infarction - a Singapore perspective

C h a p t e r 3 Acute Myocardial Infarction - Management in First 3 Hours

Myocardial infarction

Emergency physician versus cardiologistinitiated thrombolysis for acute myocardial infarction: a Singapore experience

DISCUSSION QUESTION - 1

The role of thrombolytic drugs in the management of myocardial infarction

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

POSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002)

ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI): DECREASING THE TIME TO TREATMENT IN THE ED

A. W. J. van t Hof, A. Liem, H. Suryapranata, J. C. A. Hoorntje, M.-J de Boer and F. Zijlstra

form of ACS, accounting for 25%-40% of MI presentations with in-hospital mortality of 5%-6% in the developed countries. 5

Influence of Treatment Delay on Infarct Size and Clinical Outcome in Patients With Acute Myocardial Infarction Treated With Primary Angioplasty

Objectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?

Myocardial Infarction In Dr.Yahya Kiwan

9/24/2013. Thrombolytics in 2013: Never Say Never. September 19 th, 2013 Scott M Lilly, MD PhD. Clinical Case

Results of Ischemic Heart Disease

ST-elevation myocardial infarctions (STEMIs)

Role of Early 2D Echocardiography in Patient with Acute Myocardial Infarction in Correlation with Electrocardiography and Clinical Presentation

ST-SEGMENT RESOLUTION: A CRITERION OF SUCCESSFUL THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION

PRIMARY CORONARY ANGIOPLASTY VERSUS INTRAVENOUS THROMBOLYSIS FOR ACUTE MYOCARDIAL INFARCTION - A COMPARATIVE STUDY AT QUEEN ALIA HEART INSTITUTE

Can Myocardial Infarction Be Rapidly Identified in Emergency Department Patients Who Have Left Bundle-Branch Block?

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

Medicine Dr. Omed Lecture 2 Stable and Unstable Angina

MYOCARDIALINFARCTION. By: Kendra Fischer

Advanced Multi-Layer Speckle Strain Permits Transmural Myocardial Function Analysis in Health and Disease:

Quinn Capers, IV, MD

Practitioner Education Course

Acute myocardial infarction. Cardiovascular disorders. main/0202_new 02/03/06. Search date August 2004 Nicholas Danchin and Eric Durand

Journal of the American College of Cardiology Vol. 39, No. 11, by the American College of Cardiology Foundation ISSN /02/$22.

Concise Review for Primary-Care Physicians

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18

Hon-Kan Yip, MD; Chiung-Jen Wu, MD; Morgan Fu, MD; Kuo-Ho Yeh, MD; Teng-Hung Yu, MD; Wei-Chin Hung, MD; and Mien-Cheng Chen, MD

Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United

Lack of progress in cardiogenic shock: lessons from the GUSTO trials

Sustained Benefit 20 Years After Reperfusion Therapy in Acute Myocardial Infarction

Acute Coronary Syndrome. Sonny Achtchi, DO

In-hospital Mortality with Relation to Time of Presentation in Patients with Acute ST Elevation Myocardial Infarction

Acute Coronary syndrome

Ischemic Heart Disease

1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI).

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Journal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.

A Report From the Second National Registry of Myocardial Infarction (NRMI-2)

Acute Coronary Syndrome (ACS) is the consequence of

Journal of the American College of Cardiology Vol. 33, No. 3, by the American College of Cardiology ISSN /99/$20.

Severe Coronary Vasospasm Complicated with Ventricular Tachycardia

Acute Coronary Syndrome

Abortion of acute ST segment elevation myocardial infarction after reperfusion: incidence, patients characteristics, and prognosis

Essam Mahfouz, MD. Professor of Cardiology, Mansoura University

The restoration of coronary flow after an

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department

The Long and Winding Road:

Embolization of a Chronic Left Ventricular Thrombus Following Thrombolytic Treatment for Acute Myocardial Infarction

Topic. Updates on Definition of Myocardial Infarction

ST Elevation Myocardial Infarction

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

Subsequent management and therapies

plasminogen activator in acute myocardial infarction

Echo in CAD: Wall Motion Assessment

FastTest. You ve read the book now test yourself

Continuing Medical Education Post-Test

Prehospital and Hospital Care of Acute Coronary Syndrome

LEFT VENTRICULAR THROMBUS IN ACUTE MYOCARDIAL INFARCTION

PCI Strategies After Fibrinolytic Therapy

Acute Coronary Syndromes

Coronary Interventions Indications, Treatment Options and Outcomes

12 Lead EKG Chapter 4 Worksheet

The New England Journal of Medicine. Special Articles OUTCOME OF ACUTE MYOCARDIAL INFARCTION ACCORDING TO THE SPECIALTY OF THE ADMITTING PHYSICIAN

Inter-regional differences and outcome in unstable angina

ST Elevation Myocardial Infarction

Acute Myocardial Infarction. One Century of History

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Journal of the American College of Cardiology Vol. 43, No. 4, by the American College of Cardiology Foundation ISSN /04/$30.

Management of ST-elevation myocardial infarction Update 2009 Late comers: which options?

The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction

T he left ventricular ejection fraction is one of the most

(For items 1-12, each question specifies mark one or mark all that apply.)

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

STEMI: Newer Aspects in Pharmacological Treatment

Infarction is the most intensively studied

The Value of Stress MRI in Evaluation of Myocardial Ischemia

Quality Improvement Report

Pre Hospital and Initial Management of Acute Coronary Syndrome

Correlation Between Regional Wall Motion Abnormalities via 2-Dimensional Echocardiography, and Coronary Angiographic Findings

Transcription:

EFFICACY OF THROMBOLYTIC THERAPY IN PRESERVING LEFT VENTRICULAR FUNCTION FOLLOWING ACUTE MYOCARDIAL INFARCTION SUMMARY ABID AMIN KHAN, NOOR AHMED, MAIMOONA INAYAT This study is a prospective study to determine the value of thrombolytic agents in restoring patency in the infarct related artery and its consequent effect on left ventricular function. At total of 48 patients were investigated, all presenting with symptoms of chest pain. Clinical, electrocardiography and echocardiographic criteria were used to document myocardial infarction. 2-D and M-mode echocardiography was used to detect abnormalities of contraction and relaxation of myocardium. Two group of patients were formed giving thrombolytic and non thrombolytic therapy. Echocardiography was done on admission, discharge and three weeks after discharge from hospital. Patients in both group were evaluated for clinical signs of left ventricular dysfunction according to Killip criteria. The study showed a better left ventricular function in group receiving thrombolytic therapy. Patients who could not be given thrombolytic therapy showed deteriorating left ventricular function which progressed even after one week. It is concluded that addition of thrombolytic therapy definitely improves left ventricular function by restoring patency of infarct related artery, and thereby improving perfusion of ischemic myocardium. INTRODUCTION Acute myocardial infarction constitutes one of the most important causes of death of cardiovascular diseases 1. The commonest causes are due to potential complications like asystole, arrhythmias, and sudden cardiac death. The most important pathogenetic mechanism is disruption of intimal atherosclerotic plaque with superimposed fresh thrombus and vasospasm leading to total occlusion of a previously 2 partially occluded artery. The usual outcome is myocardial necrosis in the area supplied by the occluded artery. Risk factors associated with this fatal outcome are obesity, hypertension, hyperlipidemias, smoking, diabetes and family history. Myocardial infarction can lead to a variety of complications including arrhythmias papillary muscle dysfunction, ventricular aneurysm and cardiac rupture. Ventricular remodeling and dysfunction are most important late complication associated with large number late post myocardial infarct deaths. The prognosis of majority * Department of Cardiology, Bolan Medical Complex Hospital Quetta. of patients who go on to develop such complications is exceptionally grave and therefore early intervention is always recommended 4. Amongst many strategies employed principally aspirin, beta blockers, and thrombolytic therapy is recommended to ensure adequate reperfusion 5. This study was designed to determine the efficacy of streptokinase to prevent left ventricular dysfunction after myocardial infarction as compared to patients to patients receiving aspirin, beta blockers, nitrates or ACE inhibitors only. METHODS 48 patients with first episode of acute myocardial infarction were included in the study. The age group was 30-80 years and the mean age was 55 years. The diagnosis of acute myocardial infarction was documented in each case by a typical history of chest pain, serial ECG changes and cardiac enzyme elevation. 41

The electrocardiographic criteria for the diagnosis of acute myocardial infarction was appearance of Q waves greater than 0.04 seconds or tall R waves in V1 with R/S ratio more than 1 and transient ST elevation (> 2mm). 12 lead ECG was performed on admission, 12 hours and then daily for three days. Patients were treated by aspirin, morphine, nitrates, beta blockers etc. Those who had no contraindications (> 70s, >9hours chest pain, peptic ulcer and bleeding disorders) were also given thrombolytic therapy and heparin. Those patient who had history of bleeding disorders e.g peptic ulcer, documented recent streptococcal infection or other contraindications, were not given thrombolytic therapy. Both groups (thrombolytic & non thrombolytic) were evaluated for clinical signs on left ventricular dysfunction and classified according to Killip. 2 dimensional and M-mode echocardiographic studies were performed on phased array sector scanner of Toshiba SSH-140A coloured Doppler. The scan probe contained 3.75 and 2.5 MHz transducers driven through a 90 degrees sector arc. Studies were recorded on a VHS cassette. Images were then available for redisplay and evaluation in real time, slow motion and single frame format. The examinations were performed in supine or 30 degrees left lateral position. Cross sectional images of left ventricle were obtained at short and long axis through basal, mid ventricular and apical areas. Basal region was the short axis through the left ventricular cavity at mitral, mid ventricular at papillary muscle and apical area at the apex. Basal and mid ventricular regions were divided in eight segments both and the apical area in four segments thus the whole myocardium consisted of 20 segments 6. Each segment was examined for akinesia, hypokinesia, dyskinesia, and normal movement. Care was taken to ensure to examine the entire circumference of left ventricle at basal, mid and apical regions. Ejection fraction more than 55% was considered normal. Echocardiographic examinations were performed on admission, discharge and a month after discharge. RESULTS VOL. 38 NO. 3 4 JULY - DECEMBER 2005 48 Patients were both male and female with an age raging from 47 to 65 were include in the study. Both groups consisted of 24 patients. Time from onset of chest pain to the initiation of thrombolytic therapy was 4-9 hours. 45 % of patients in thrombolytic group were in Killip I, 37.5 % in II, 16.5 % in III and non in Killip IV. In non thrombolytic group 16.5 % in I, 25 % in II, 34 % in III and 25 % in Killip IV. (table 2). Post MI angina. The incidence of post myocardial infarction angina was 67 % in group receiving thrombolytic therapy and it was 12.5 % in non thrombolytic group (table 3) while in hospital. Left ventricular Function. 11 (45 %) patients of group A (thrombolytic) had normal left ventricular function on admission. This figure raised to 18 (75%) one week after discharge. In group B (non thrombolytic) number of patients with normal left ventricular function was 19 (79%) on admission and 5 (20%) on final echocardiographic evaluation (table 2 and figures 1 and 2). DISCUSSION: Acute myocardial infarction can lead to a variety of morbid complications prominent among which is left ventricular dysfunction. The underlying cause of acute myocardial infarction is thrombotic occlusion of coronary artery supplying a particular area of myocardium, leading eventually to necrosis. This invites several other complications in its wake, specifically ventricular rupture, asystole, ventricular arrhythmias and sudden death. Table 1 MI site Group A Group B Anterior 14 15 Inferior 10 9 42

Table 2 No. of patients with left Ventricular dysfunction detected by Killip classification. Figure - 2 Comparison of ejection fraction compared on discharge Group Class I Class II Class III Class IV A 11(45) 9(37.5) 4(16.5) Nil B 4 (16.5) 6(25) 8(34) 6(25) Figures in parenthesis are percent values Table 3 No. of patients with post myocardial infarction angina. A 16(67%) B 3(12.5%) Table 4 No. of patients having Ejection fraction calculated on three echocardiographic studies in GROUP A Figure - 3 Ejection fraction compared in both groups one week after discharge Ejection On Admission On Discharge 1week after Fraction 40-45% 2(8) 1 (1) 2(8) 45-50% 4(16) 5(20) 3(12.5) 50-55% 7(29) 7(29) 1 (1) 55-60% 7(29) 3(12.5) 9(37) 60 and above 14(16) 18(33) 9(37) Figures in parenthesis are percent values. Table 5 No. of patients having Ejection fraction in Group B Ejection On Admission On Discharge 1week after Fraction 40-45% 1(4) 5(20) 5(20) 45-50% 1(4) 5(20) 7(29) 50-55% 3(12.5) 3(12.5) 7(29) 55-60% 5(20) 4(16) 2(8) 60 and above 14(58) 7(29) 3(12.5) Figures in parenthesis are percent values. Figure - 1 Comparison on echocardiography done on in both groups The acute episode is usually triggered by disruption of a plaque with superimposed thrombosis and vasospasm. Thrombosis follows as a result of subendothelial collagen being exposed to blood components leading to activation of platelets and their adherence to the ruptured plaque. This is why early thrombolysis has beneficial effect on complication of acute myocardial infarction 7. The time interval for thrombolytic therapy is ideally 4-9 hours, as was in this study, but late thrombolysis has been shown to have positive long term benefits. This is related to the benefit conferred by patency of infarct related artery 8. The beneficial effects are further potentiated when an effective antithrombolytic regimen like antiplatelet and anticoagulant therapy is added 9,10,11. This is because the site of occlusion remains highly thrombogenic due to residual fibrin and this thrombogenic state is counter acted by antiplatelets and anticoagulants effectively. The ejection fraction of patients receiving thrombolytic therapy in the study was higher then 43

those who did not. This can partially be explained by the ability of the streptokinase to forestall the wave of infarction spreading from the infarct area 12, 13.. by salvaging the ischemic myocardium in the vicinity of infarct area, thrombolytic therapy can improve left ventricular function. Variouse other studies have shown streptokinase to have clear benefit in complications after acute myocardial infarction then those who did not. Anistreplase, Alteplase and rtpa have also been evaluated in several studies documenting improvement in left ventricular function after myocardial infarction14,15,16. Frank left ventricular dysfunction after myocardial infarction results when atleast 40% of the functioning myocardium is lost17. This complication can lead to cardiogenic shock with a fatal outcome18,19. Killip grading is most useful to detect left ventricular dysfunction at bedside. Echocardiography give valuable information regarding wall motion and ejection and was therefore used as a major investigation to detect left ventricular dysfunction in this study. Measurement of CK-BM has also been used to detect patency of the infarct related artery20.21. Left ventricular dysfunction after myocardial infarction can be effectively treated by ACE inhibitors22, 23, and 24. Many clinicians initially feared that the wide spread use of thrombolytic therapy would create an increased demand for follow up procedures including surgical revascularization. The higher incidence (67%) of post myocardial infarct angina in this study confirms theses doubts, raising the need for intervention in all patients receiving thrombolytic therapy. CONCLUSION: Thrombolytic therapy with streptokinase has shown to have positive effects over ventricular performance affected adversely by acute myocardial infarction. This study highlights the beneficial effects of thrombolytic therapy given along anti platelets and anticoagulants in preserving left ventricular function after myocardial infarction in local population at Quetta. VOL. 38 NO. 3 4 JULY - DECEMBER 2005 REFERENCES 1. Gruppo Italiano per lo studio della streptochinasi nell' Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute mycoardial infarction.lancet 1986;1:397-401. 2. DeWood MA, Spores J,Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction N Engl J;Med 1980 ;303:897-902. 3. Nicolosi GL'Latini R, Marino P,et al. prognostic value of predischarge quantitative two dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 trial eur Heart J 1996;11:1646-1656. 4. Fibrinolytic therapy trails (FTT) Collaborative Group. Stress ECG and Coronary angiography for any possible intervention like PTCA and CABG. Lancet 1994; 343:311-322. 5. ISIS-2 (Second International Study of infarct Survival collaborative group randomized trail of intravenous streptokinase, oral aspirin, both, or neither among 17,187cases if suspected acute myocardial infarction :ISIS-2, Lancet 1988;2:349-360. 6. Report of the American Association of echocardiogram on nomenclatures and standards. Identification of myocardial wall segments Nov.82 (Quoted Harvey Feigenbaum, echocardiogram in coronary artery disease edited by himself). 7. The GUSTO angiographic investing the effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl JMed. 1993;329:1619-1622. 8. Sherry S, Marder VJ. Streptokinase and recombinant tissue plasminogen activator (r-tpa) are equally effective intreating acute myocardial infarction. am Int Med. 1991;114:417-423. 44

9. Giugliano RP.Mc Cabe CH, Antman EM, et al. the thrombolysis in myocardial infarction (TIMI) investigators. Lower dose heparin with fibrinolysis is associate with lower rates of intracranial hemorrhage. Am Heart J 2001;141:742750. 10. Gruppo Italiano per lo studio della sopravvivenza nelpingarto miocardico. GISSI-2: Factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71. 11. Mc Mohan S,Collins R, Knitght C, Yusuf S, Peto R.Reduction of major morbidity and mortality with heparin in acute myocardial infarction. Criculation1988;78,Suppl 11:1119 (abs). 12. Reimer KA, Jennings RB. The "wavefront phenomenon" of myocardial ischaemic death. Transmural progression of mecrosis within the framework of ischaemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979:40:633-644. 13. Goa K-L, Henwood JM,Stolz JF5 et al Intravenous streptokinase:a reappraisal of it's Therapeutical use in Acute Myocardial Intarction. Drugs 1990;39(5):693-719. 14. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682. 15. Lee KL, Califf RM, Simes J, et al. Holding GUSTO up to light:gl9obal Utilization of streptokinase and Tissue Plasminogen activator for Occluded Coronary Arteries. Ann intern Med. 1994;120:876-881. 16. Verstraete M. Third generation thrombolytic drugs.am J Med.2000;109:52-58. 17. L. David Hillis, Richard A Lange, Michael D Winniford, Richard L. Page, thrombolytic therapy of myocardial infarction. Manual of clinical problems in cardiology, lippincott & Williams 2003;39:168-171. 18. Goldberg w, Gore M. Thompson CA, et al Recent magnitude of and temporal trends (1994-1997) in the incidence an Hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second national registry of myocardial infarction Am Heart J 2001;141:65-72. 19. Page M, Caulfield JB, Kastor JA, et al Myocardial changes associated with cardiogenic shock. N Engl J Med. 1971;285:133-137. 20. Tanasijevic W, Cannon CP. Antman EM, et al. Myoglobin, creatinime kinase-mb and cardiac troponin-160 minute ratios predict infarct related artery patency after thrombolysis for acute myocardial infraction: result from the thrombolysis in myocardial infarction study (TIMI) 1 10B. J Am Coll Cardiol 1999;34:739-747. 21. Lewis BS, Ganz W, Laramee P et al (1988) Usefulness of a rapid initial increase in plasma creatine kinase activity as a marker of reperfusion during thrombolytic therapy for acute myocardial infarction. Am. J Cardiol.,62:20-4. 22. ISIS-4 collaborative group. A randomized trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685. 23. Kober L, Torp-Pederson C, Carlsen JE, etal. A clinical trial of the angiotensinonverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl JMed. 1995;333:16701676. 24. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators. Effect of Ramipril on mortality and mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342-828. 45